Prevention of amputation by neoadjuvant therapy with pembrolizumab in acrolentiginous melanoma

J Eur Acad Dermatol Venereol. 2024 Sep;38(9):e820-e822. doi: 10.1111/jdv.19920. Epub 2024 Feb 29.

Authors

Inga Hansen¹, Alessandra Rünger¹, Clara Noebel¹, Glenn Geidel¹, Julian Kött¹, Anne Menz², Lina Hildebrandt¹, Stefan W Schneider¹, Christoffer Gebhardt¹

Affiliations

¹ Department of Dermatology and Venereology, University Skin Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
² Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

PMID: 38421077
DOI: 10.1111/jdv.19920

No abstract available

Publication types

Letter
Case Reports

MeSH terms

Amputation, Surgical*
Antibodies, Monoclonal, Humanized* / therapeutic use
Antineoplastic Agents, Immunological / therapeutic use
Humans
Melanoma* / drug therapy
Melanoma* / surgery
Neoadjuvant Therapy*
Skin Neoplasms* / drug therapy
Skin Neoplasms* / pathology

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
pembrolizumab